基于知识的机械模型准确地预测了EGFR突变肺腺癌中gefitinib的疾病进展
Adèle L'Hostis1, Jean-Louis Palgen1, Angélique Perrillat-Mercerot1
1Novadiscovery SA, Pl. Giovanni da Verrazzano, Lyon, 69009, Rhône, France.
NPJ systems biology and applications
|July 31, 2023
概括
一个新的计算模型,ISELA,预测肺腺癌 (LUAD) 进展在EGFR突变患者治疗gefitinib. 该工具通过模拟瘤进化和抗药性来帮助开发LUAD的新疗法.
科学领域:
- 在瘤学瘤学.
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺腺癌 (LUAD) 在晚期预后不佳.
- 像EGFR抑制剂这样的向疗法可以改善结果,但却面临抗药性.
- 开发用于LUAD的新疗法需要预测模型.
研究的目的:
- 为了介绍In Silico EGFR突变LUAD (ISELA) 模型.
- 将患者的特征和遗传异质性与瘤进展联系起来.
- 评估该模型在LUAD中对gefitinib治疗的预测价值.
主要方法:
- 开发了EGFR突变LUAD的转化机制模型 (ISELA).
- 关于LUAD,遗传异质性和gefitinib的综合知识.
- 在体外,异种移植和人类数据上对模型进行校准.
- 根据Lux-Lung 7临床试验数据验证了模型.
主要成果:
- ISELA模型重现了超过90%的实验数据.
- 该模型准确地预测了从Lux-Lung 7试验 (覆盖率98.5%) 到进展的时间.
- 该模型显示了对gefitinib治疗结果的高预测价值.
结论:
- 伊塞拉模型是了解EGFR突变LUAD的一个有价值的工具.
- 这种机制模型可以支持开发新的LUAD疗法.
- 该模型可以作为在临床试验中生成合成控制臂的基础.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
相关概念视频
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K